Gastroesophageal reflux disease (GERD) is a condition in which the stomach? GERD is a clinical syndrome characterized by heartburn caused by the reflux of duodenal contents into the esophagus? GERD is a clinical syndrome characterized by heartburn and acid reflux. GERD has a long course and is prone to recurrence, and most patients require long-term medication. GERD may be associated with both benign and malignant complications. Benign complications include erosive esophagitis, bleeding and GI strictures, while malignant or potentially malignant complications include Barrett’s esophagus (Barrett’s esophagus) metaplasia and esophageal adenocarcinoma. Below, we introduce the clinical characteristics and management of Barrett’s esophagus chemosis and esophageal adenocarcinoma, malignant complications of GERD. 1.Barrett’s esophagus chemosis – the transitional stage of esophageal adenocarcinoma Barrett’s esophagus refers to the squamous epithelium of the lower esophagus covered by columnar epithelium. 10% to 15% of GERD patients will develop Barrett’s esophagus, and the risk of developing esophageal adenocarcinoma based on Barrett’s esophagus is 30 to 60 times higher than that of the general population. A growing number of studies have demonstrated that Barrett’s esophagus is a transitional stage in the progression from GERD to esophageal adenocarcinoma. In view of this early detection of Barrett’s esophagus is very important. Unfortunately, Barrett’s esophagus is usually asymptomatic and its symptoms are mostly caused by GERD and its complications. Patients with asymptomatic Barrett’s esophagus are often seen clinically. Countermeasures: If a patient has developed Barrett’s esophagus, the physician will administer a proton pump inhibitor, which is the drug of choice in internal medicine for Barrett’s esophagus, at a higher dose, and after the symptoms are controlled, the patient is treated with a small maintenance dose. The results of the study show that long-term proton pump inhibitor therapy can shorten the length of Barrett’s esophagus lesions, and some of the esophageal mucosa can even be reversed back to squamous epithelium, but it is difficult to achieve complete reversal. Thus, proton pump inhibitors can stop the progression of Barrett’s esophagus and reduce the risk of malignant transformation to esophageal adenocarcinoma. If Barrett’s esophagus has developed esophageal mucosal heterogeneous hyperplasia, the risk of malignant transformation to esophageal cancer is further increased, especially in severe heterogeneous hyperplasia, which will inevitably become cancerous. At this time, the doctor will perform endoscopic mucosal resection for the patient. 2.Esophageal cancer – malignant complication of GERD Early symptoms of esophageal cancer are often not obvious, only when swallowing hard food, patients may have different degrees of discomfort, including mild obstructive sensation when eating, burning, pinching or pulling pain behind the sternum. When food passes slowly, the patient may experience a sensation of stagnation or foreign body. Sometimes the symptoms may be mild or severe, so patients should not let down their guard because of the temporary relief of symptoms. Countermeasure: If a patient is unfortunate to have esophageal cancer, doctors will make different treatment plans according to the stage of the tumor. For early-stage esophageal cancer limited to mucosal layer, doctors will recommend patients to undergo endoscopic mucosal resection or endoscopic submucosal dissection for more satisfactory results after surgery. If the lesion has invaded to the submucosal layer or even deeper, endoscopic resection is not possible and the doctor will perform radical esophagectomy for the patient. As for middle and late stage esophageal cancer, at present, the clinic adopts multidisciplinary comprehensive treatment, and the treatment effect is poor at this time Gastroesophageal reflux disease has a significant impact on patients’ quality of life, so it should be treated actively and start from the etiology to avoid or eliminate the risk factors of GERD, reduce GERD symptoms, reduce the stimulation of gastric acid and other digestive juices on esophageal mucosa, and reduce the incidence of esophagitis and Barrett’s esophagus. Generally speaking, most patients with GERD do not develop malignancy, but the small percentage of patients who develop Barrett’s esophagus should be given special attention. Timely detection of the condition is crucial in the case of Barrett’s esophagus heterogeneous hyperplasia or in the early stages of esophageal cancer, when endoscopic treatment is effective; if it progresses to mid- to late-stage esophageal cancer, comprehensive multidisciplinary treatment should be performed in an oncology center experienced in treatment.